PAtHways to Improved Care
0.25 hr(s)
May 17, 2021
May 17, 2022
Victor Tapson, MD
Professor of Medicine
Director, Venous Thromboembolism and Pulmonary Vascular Disease Research Program
Director, Clinical Research, Women’s Guild Lung Institute
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Embolism Response Team
Cedars-Sinai Medical Center
Los Angeles, CA
Has the pandemic impacted your patients with PAH? Have you changed your care of these patients? In this short CME-certified vlog, leading pulmonologist Dr. Victor Tapson, Director, Pulmonary Vascular Disease Research at Cedars-Sinai Medical Center, discusses how the pandemic has impacted his patients and reviews available evidence on reducing risks in PAH patients during the pandemic. He also touches on changes he has made in his approach to the diagnosis of PAH patients during the pandemic.
This activity is intended for pulmonologists, cardiopulmonologists, cardiologists, and AHPs managing patients with PAH.
Patients with PAH are a high-risk group for mortality with COVID-19 infection. Clinicians require ongoing education on management across PAH functional classes and disease classifications/risk stratifications, including available evidence. Upon completion of this activity, clinicians will be better able to interpret evidence and recommendations for managing their patients with PAH during the pandemic.
Upon completion of this activity, participants will be able to:
Review the latest epidemiological data to develop risk mitigation strategies in PAH patients
Recommend treatment selection and management for different PAH functional classes and risk classifications during the pandemic
This activity will take approximately 15-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Victor Tapson, MD, (Faculty)
Advisor or Review Panel Member: Bristol Myers Squibb, Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Occasional): Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Retained): Thrombolex, Inc. and V-Wave Ltd.
Grant/Research Support Recipient: Bristol Myers Squibb, Eli Lilly and Company, Genentech, United Therapeutics, Verily Life Sciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
0.25 hr(s)
May 28, 2021
May 28, 2022
Victor Tapson, MD
Professor of Medicine
Director, Venous Thromboembolism and Pulmonary Vascular Disease Research Program
Director, Clinical Research, Women’s Guild Lung Institute
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Embolism Response Team
Cedars-Sinai Medical Center
Los Angeles, CA
Are you taking the right precautions to ensure your patients with PAH are safely managed during COVID-19? Are you employing effective therapeutic management strategies with your PAH patients during the pandemic? In this short CME-certified vlog, leading pulmonologist Dr. Victor Tapson, Director, Pulmonary Vascular Disease Research at Cedars-Sinai Medical Center, discusses how to effectively manage therapy for PAH during the pandemic, including those who are COVID-19-infected, taking into account the evidence and guidelines to facilitate effective therapeutic management.
This activity is intended for pulmonologists, cardiopulmonologists, cardiologists, and AHPs managing patients with PAH.
Clinicians who manage patients with PAH require increased competency in managing therapeutic regimens, including in those who are infected with COVID-19. It is critical for PAH patients to take precautions against COVID-19 to prevent disease progression and for physicians to ensure patients are well controlled to decrease the risk of severe illness if a patient does become infected. Upon completion of this activity, clinicians will be better able to facilitate effective therapeutic management and perform timely treatment adjustments to ensure better patient outcomes during the COVID-19 pandemic.
Upon completion of this activity, participants will be able to:
Recommend treatment selection and management for different PAH functional classes and risk classifications during the pandemic
Review the latest epidemiological data to develop risk mitigation strategies in PAH patients
This activity will take approximately 15-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Victor Tapson, MD, (Faculty)
Advisor or Review Panel Member: Bristol Myers Squibb, Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Occasional): Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Retained): Thrombolex, Inc. and V-Wave Ltd.
Grant/Research Support Recipient: Bristol Myers Squibb, Eli Lilly and Company, Genentech, United Therapeutics, Verily Life Sciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: EUA vaccines and therapies for COVID-19
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
0.25 hr(s)
June 11, 2021
June 11, 2022
Victor Tapson, MD
Professor of Medicine
Director, Venous Thromboembolism and Pulmonary Vascular Disease Research Program
Director, Clinical Research, Women’s Guild Lung Institute
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Embolism Response Team
Cedars-Sinai Medical Center
Los Angeles, CA
Very few studies have assessed the impact of healthcare disparities on PAH, despite the potential adverse impacts. One such study from Talwar et al reported that minority PAH patients may be at risk for worse outcomes due to lack of healthcare access, insurance gaps, and socioeconomic status. Dr. Victor Tapson, Director, Pulmonary Vascular Disease Research at Cedars-Sinai Medical Center, draws from his own experience of treating PAH patients and shares how increased awareness and education can improve outcomes for all patients.
This activity is intended for pulmonologists, cardiopulmonologists, cardiologists, and AHPs managing patients with PAH.
There are few studies that have assessed the impact of healthcare disparities on PAH. Given the potential impact healthcare disparities have on pulmonary arterial hypertension (PAH) outcomes, clinicians require education to increase awareness of these health disparities. Upon completion of this activity, clinicians will be able to interpret up-to-date knowledge of the emerging studies to increase their awareness and improve outcomes in PAH patients.
Upon completion of this activity, participants will be able to:
Discuss the impact healthcare disparities have on PAH care and outcomes
Outline strategies to address disparities faced by patients with PAH
This activity will take approximately 15-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Victor Tapson, MD, (Faculty)
Advisor or Review Panel Member: Bristol Myers Squibb, Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Occasional): Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Retained): Thrombolex, Inc. and V-Wave Ltd.
Grant/Research Support Recipient: Bristol Myers Squibb, Eli Lilly and Company, Genentech, United Therapeutics, Verily Life Sciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
0.25 hr(s)
June 28, 2021
June 28, 2022
Jen C.
BioNews Columnist
Pulmonary Hypertension News
PH Forum Moderator
PAH patient and advocate, Jen, shares her perspective, experience, and challenges with managing her PAH every day and during her COVID-19 infection. Learn from her journey and consider how her experiences may improve your own PAH patients’ outcomes.
This activity is intended for pulmonologists, cardiopulmonologists, cardiologists, and AHPs managing patients with PAH.
Patients with PAH face everyday challenges and are a high-risk group for complications from COVID-19 infection. Upon completion of this activity, clinicians will be better able to counsel and guide their patients with PAH, including during the challenging times of the pandemic.
Upon completion of this activity, participants will be able to:
Discuss strategies to assist PAH patients with their care
Outline the impact of COVID-19 on patients with PAH
This activity will take approximately 15-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the evaluation.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Jen (Patient Advocate) has no financial relationships to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
0.50 hr(s)
June 28, 2021
June 28, 2022
John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
Director, Pulmonary Hypertension Comprehensive Care Center
Medical Director, Cardiovascular Medical Unit
University of Utah Hospital
Faculty Director of Cardiology Education
University of Utah School of Medicine
Salt Lake City, UT
In this short “How I Do It” vlog, expert faculty Dr. John Ryan, Director, Pulmonary Hypertension Comprehensive Care Center, University of Utah Hospital showcases personal experiences incorporating updated recommendations in clinical practice as well as diagnostic approaches, screening methods, and the importance of risk assessment. Upon completion of this activity, clinicians will be better able to incorporate effective screening techniques and appropriate diagnostic and risk assessment tools within clinical practice to improve outcomes for patients with PAH.
This activity is intended for pulmonologists, cardiologists, cardiopulmonologists, and other healthcare providers (MDs, PAs, and NPs) interested in treating patients with PAH.
The differential diagnosis of PAH is challenging, and diagnostic delays are common, leading to poorer patient outcomes. Clinicians require ongoing education on diagnostic algorithms and tools, patient populations appropriate for screening, and risk assessment methods to guide patient management. Upon completion of this activity, clinicians will be better able to apply appropriate diagnostic methods and risk assessment tools to enhance their recognition and management of PAH.
Upon completion of this activity, participants will be able to:
Discuss recent changes to the clinical definition of PAH and their relevance to clinical practice
Describe best practices for the use of algorithms and tools to improve diagnosis of PAH
Apply risk assessment strategies to inform multidimensional approaches to the management of PAH
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA (Faculty)
Advisory Board: Bayer and Janssen PH
Consultant: Vertex
Speakers Bureau: Bayer, Janssen PH, United therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
Diagnostic tools and algorithm
Screening
Risk assessment
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
0.75 hr(s)
July 14, 2021
July 14, 2022
Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Victor Tapson, MD
Professor of Medicine
Director, Venous Thromboembolism Research
Director, Clinical Research, Women’s Guild Lung Institute
Associate Director, Division of Pulmonary and Critical Care
Director, Pulmonary Vascular Disease Research
Cedars-Sinai Medical Center
Los Angeles, CA
In this clinical commentary, join cardiology expert Dr. Vallerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan and pulmonology expert Dr. Victor Tapson, Director, Pulmonary Vascular Disease Research at Cedars-Sinai Medical Center as they provide real-world advice on the management of pulmonary arterial hypertension (PAH). These experts will discuss their best practices for:
Risk assessment and stratification
Use of oral combination therapies
Management of PAH patients during COVID-19
Dr. McLaughlin and Dr. Tapson also provide their insights into the future of PAH management, with a discussion of emerging therapeutic options.
This activity is intended for pulmonologists, cardiologists, cardiopulmonologists, and other healthcare providers (MDs, PAs, and NPs) interested in treating patients with PAH.
Treatment selection for patients with pulmonary arterial hypertension (PAH) is complex, when considering the number of therapies, combinations of different therapies, and recent updates to treatment guidelines. Clinicians require ongoing education on the most recent guideline recommendations and treatment algorithms, and how to apply these recommendations in their practices. Clinicians will learn best practices for risk assessment and treatment of PAH to increase competency of PAH management, and will learn about the management of PAH patients during COVID-19. Upon completion of this activity, clinicians will be better able to apply treatment algorithms and risk assessment to improve PAH patient care.
Upon completion of this activity, participants will be able to:
Evaluate current real-world practices for the management of PAH with combination therapy and within the context of COVID-19
Review recent clinical data that inform the safety and efficacy of individual PAH treatments and combination therapies
Discuss emerging clinical research initiatives in PAH and their potential impact on both current and future patient care plans
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Vallerie McLaughlin, MD (Faculty)
Consultant (Retained): Acceleron Pharma, Inc., Actelion Pharmaceuticals US, Inc., Altavant Sciences, Inc., Caremark, CiVi Biopharma, Inc., Gossamer Bio, Liquidia, United Therapeutics
Grant/Research Support Recipient: Acceleron Pharma, Inc., Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., Reata Pharmaceuticals Inc., SonoVie, United Therapeutics
Victor Tapson, MD, (Faculty)
Advisor or Review Panel Member: Bristol Myers Squibb, Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Occasional):Actelion Pharmaceuticals US, Inc., Janssen, Johnson & Johnson, United Therapeutics
Consultant (Retained): Thrombolex, Inc. and V-Wave Ltd.
Grant/Research Support Recipient: Bristol Myers Squibb, Eli Lilly and Company, Genentech, United Therapeutics, Verily Life Sciences
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Sotatercept for the management of PAH
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
2019 Recommendations From the 6th World Symposium on Pulmonary Hypertension and CHEST Guidelines
Impactful Publications From 2020
Experiences With Combination Therapy in Clinical Practice
COVID-19 and PAH
Emerging Treatments for PAH
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
0.50 hr(s)
July 27, 2021
July 27, 2022
Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI
Are you interested in finding out how you can more effectively manage your patients with PAH? In this short “How I Do It” vlog, expert faculty Dr. Vallerie McLaughlin, Director of the Pulmonary Hypertension Program at the University of Michigan discusses recommendations for the use of oral combination therapies in PAH along with her experiences and considerations with these treatment options in clinical practice. Stay on the right PAHth with therapeutic options available for your patients with PAH and hear more on:
Treatment selection according to risk assessment
Considerations for oral combination therapy
Experiences with oral combination therapy
Emerging therapies for PAH
This activity is intended for pulmonologists, cardiologists, cardiopulmonologists, and other healthcare providers (MDs, PAs, and NPs) interested in treating patients with PAH.
Pulmonary arterial hypertension (PAH) is a progressive disorder in which endothelial dysfunction and vascular remodeling obstruct small pulmonary arteries, resulting in increased pulmonary vascular resistance and pulmonary pressures. Treatment selection is complex, when considering the number of therapies, combinations of different therapies, and recent updates to treatment guidelines. Clinicians require ongoing education on the most recent guideline recommendations and how to apply these guidelines in their practices. Clinicians will learn best practices for risk assessment and treatment of PAH to increase competency of PAH management. Upon completion of this activity, clinicians will be better able to apply treatment algorithms and risk assessment to improve PAH patient care.
Upon completion of this activity, participants will be able to:
Evaluate current real-world practices for the management of PAH with combination therapy
Review recent clinical data that inform the safety and efficacy of individual PAH treatments and combination therapies
Discuss emerging clinical research initiatives in PAH and their potential impact on both current and future patient care plans
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Vallerie McLaughlin, MD
Consultant (Retained): Acceleron Pharma, Inc., Actelion Pharmaceuticals US, Inc., Altavant Sciences, Inc., Caremark, CiVi Biopharma, Inc., Gossamer Bio, Liquidia, United Therapeutics
Grant/Research Support Recipient: Acceleron Pharma, Inc., Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., Reata Pharmaceuticals Inc., SonoVie, United Therapeutics
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Sotatercept for the management of PAH
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
Treatment selection according to risk assessment and algorithms
Oral combination therapy considerations
Experiences with combination therapy in practice
Emerging therapies
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
0.50 hr(s)
November 29, 2021
November 29, 2022
Dan Schuller, MD
Professor and Chair
Department of Internal Medicine – Transmountain
Texas Tech University Health Sciences Center
Paul L. Foster School of Medicine
El Paso, TX
How can clinicians improve early detection of PAH? What are some practical strategies for managing PAH patients in today’s world? What recent data support current treatment strategies, and what are emerging therapeutic options? This 30-minute multimedia Q&A touchpoint “Hot Topics” CME activity features leading pulmonology expert Dan Schuller, MD, from Texas Tech University Health Sciences Center who discusses the latest data and recommendations, along with his insights for applying this information in clinical practice. This activity features engaging images, charts, and short video snippets. Dive into recommendations from the 6th World Symposium on Pulmonary Hypertension, new risk assessment tools, and more!
This activity is intended for pulmonologists, cardiologists, cardiopulmonologists, and other healthcare providers (MDs, PAs, and NPs) interested in treating patients with PAH.
The diagnosis of PAH is challenging, and diagnostic delays are common, leading to poorer patient outcomes. In addition, treatment selection for patients with PAH is complex when considering the number of therapies, combinations of different therapies, and recent updates to treatment guidelines. Clinicians require ongoing education on diagnostic algorithms, patient populations appropriate for screening, risk assessment methods to guide patient management, and recent clinical trial data to support treatment selection. Clinicians will also learn about timely real-world aspects of patient care, including management of PAH patients during the COVID-19 pandemic. Upon completion of this activity, clinicians will be better able to apply appropriate diagnostic/screening methods, risk assessment tools, recent clinical data, and expert insights on real-world best practices to enhance their recognition and management of PAH in clinical practice.
Upon completion of this activity, participants will be able to:
Discuss current best practices and recommendations for PAH screening, diagnosis, risk assessment, and multidisciplinary real-world care
Review recent clinical data that inform the safety and efficacy of individual PAH treatments and combination therapies
List emerging clinical research initiatives in PAH and their potential impact on both current and future patient care plans
This activity will take approximately 30-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
Dan Schuller, MD, has no financial relationships to disclose.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Rodatristat ethyl, CS1, seralutinib, AV-101, treprostinil palmitil inhalation powder, radiofrequency ablation catheter, treprostinil DPI, and sotatercept
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.)
Screening and diagnosis of PAH
Evolution of risk assessment in treatment selection
Recent clinical data and approvals
Real-world management of PAH
Emerging therapies
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson
Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
Compatible with Windows PC and MAC (256 MB of RAM or higher)
Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
Adobe Reader to print certificate. Click here to download Adobe Reader for free.
Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Michelle Forcier
mforcier@achlcme.org
